UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


Form 10-Q/A

Amendment No. 1


(Mark One)


   X .   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the quarterly period ended June 30, 2011


        .   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


For the transition period from ______________________________ to ______________________________


Commission File Number 33-55254-41


BIOETHICS, LTD.

(Exact name of registrant as specified in charter)

 

 

NEVADA

87-0485312

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

 

1137 N. 120 W., American Fork, Utah

84403

(Address of principal executive offices)

(Zip Code)

 

 

(505) 681-4210

(Issuer’s telephone number, including area code)

 

 

Not Applicable

(Former name, former address, and former fiscal year, if changed since last report)


Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  

            Yes   X .     No         .


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  

          Yes   X .     No         .


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.


Large accelerated filer

        .

Accelerated filer

        .

Non-accelerated filer

        .

Smaller reporting company

   X .


Indicate by check mark whether the issuer is a shell company (as defined in rule 12b-2 of the Exchange Act).

Yes    X .     No         .

      

As of August 1, 2011, the issuer had outstanding 11,000,000 shares of common stock, par value $0.001.




1




Explanatory Note

The purpose of this Amendment No. 1 to the Quarterly Report on Form 10-Q of Bioethics, Ltd. for the quarterly period ended June 30, 2011, filed with the Securities and Exchange Commission on August 15, 2011 (the “Form 10-Q”), is solely to furnish Exhibit 101 to the Form 10-Q in accordance with Rule 405 of Regulation S-T. Exhibit 101 to this report provides the consolidated financial statements and related notes from the Form 10-Q formatted in XBRL (eXtensible Business Reporting Language).

No other changes have been made to the Form 10-Q.  This Amendment No. 1 to the Form 10-Q speaks as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to the original filing date, and does not modify or update in any way disclosures made in the original Form 10-Q.

Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.



Item 6.

Exhibits


The following documents are included as exhibits to this report:


(a) Exhibits


Exhibit

Number

 

SEC Reference Number

 



Title of Document

 



Location

 

 

 

 

 

 

 

  3.1

 

3

 

Articles of  Incorporation

 

Incorporated by Reference*

  3.2

 

3

 

Bylaws

 

Incorporated by Reference*

10.1

 

10

 

Promissory Note dated May 10, 2011

 

Original Filing

10.2

 

10

 

Promissory Note dated June 27, 2011

 

Original Filing

31.1

 

31

 

Section 302 Certification of Chief Executive and Chief Financial Officer

 

Original Filing

32.1

 

32

 

Section 1350 Certification of Chief Executive and Chief

Financial Officer

 

Original Filing

101.INS**

 

 

 

XBRL Instance Document

 

This Filing

101.SCH**

 

 

 

XBRL Taxonomy Extension Schema

 

This Filing

101.CAL**

 

 

 

XBRL Taxonomy Extension Calculation Linkbase

 

This Filing

101.DEF**

 

 

 

XBRL Taxonomy Extension Definition Linkbase

 

This Filing

101.LAB**

 

 

 

XBRL Taxonomy Extension Label Linkbase

 

This Filing

101.PRE**

 

 

 

XBRL Taxonomy Extension Presentation Linkbase

 

This Filing


 

*Incorporated by reference to Exhibits 3(i) and 3(ii) of the Company’ 2003 Form 10-KSB report, filed March 30, 2004.


**XBRL information is furnished and not filed for purposes of Sections 11 and 12 of the Securities Act of 1933 and Section 18 of the Securities Exchange Act of 1934, and is not subject to liability under those sections, is not part of any registration statement or prospectus to which it relates and is not incorporated or deemed to be incorporated by reference into any registration statement, prospectus or other document.




2





SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.




 

Bioethics, Ltd.

 

 

 

 

Date:  August 25, 2011

By /s/ Jed Beck                                        

 

Jed Beck

 

President, Chief Executive Officer and

 

Chief Financial Officer

 

(Principal Executive and Financial Officer)







3



Bioethics (PK) (USOTC:BOTH)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Bioethics (PK)
Bioethics (PK) (USOTC:BOTH)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Bioethics (PK)